共 118 条
[1]
Buttel IC(2011)Taking immunogenicity assessment of therapeutic proteins to the next level Biologicals 39 100-109
[2]
Chamberlain P(2008)Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products J Immunol Methods 333 1-9
[3]
Chowers Y(2004)Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products J Immunol Methods 289 1-16
[4]
Ehmann F(2008)Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products J Pharm Biomed Anal 48 1267-1281
[5]
Greinacher A(2007)A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs Nat Biotechnol 25 555-561
[6]
Jefferis R(2009)A bioactive drug quantitation based approach for the detection of anti-drug neutralizing antibodies in human serum J Immunol Methods 345 70-79
[7]
Koren E(2017)Drug target interference in immunogenicity assays: recommendations and mitigation strategies AAPS J 19 1564-1575
[8]
Smith HW(2018)A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers J Thromb Haemost 16 1722-1731
[9]
Shores E(1994)Heterogeneity of plasma tissue factor pathway inhibitor Blood Coagul Fibrinolysis 5 551-559
[10]
Shankar G(2018)Translational pharmacokinetic/pharmacodynamic characterization and target-mediated drug disposition modeling of an anti-tissue factor pathway inhibitor antibody, PF-06741086 J Pharm Sci 107 1995-2004